1 |
Elia G, Patrizio A, Ragusa F, Paparo SR, Mazzi V, Balestri E, Botrini C, Rugani L, Benvenga S, Materazzi G, Spinelli C, Antonelli A, Fallahi P, Ferrari SM. Molecular features of aggressive thyroid cancer. Front Oncol 2022;12:1099280. [PMID: 36605433 DOI: 10.3389/fonc.2022.1099280] [Reference Citation Analysis]
|
2 |
Li G, Chen W, Gong Y, Wei T, Gong R, Zhu J, Li Z, Lei J. Identification of Circulating Exosomal microRNAs Associated with Radioiodine Refractory in Papillary Thyroid Carcinoma. J Pers Med 2022;12. [PMID: 36556238 DOI: 10.3390/jpm12122017] [Reference Citation Analysis]
|
3 |
Zeng L, Yuan S, Zhou P, Gong J, Kong X, Wu M. Circular RNA Pvt1 oncogene (CircPVT1) promotes the progression of papillary thyroid carcinoma by activating the Wnt/β-catenin signaling pathway and modulating the ratio of microRNA-195 (miR-195) to vascular endothelial growth factor A (VEGFA) expression. Bioengineered 2021;12:11795-810. [PMID: 34927541 DOI: 10.1080/21655979.2021.2008639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
4 |
Li LR, Du B, Liu HQ, Chen C. Artificial Intelligence for Personalized Medicine in Thyroid Cancer: Current Status and Future Perspectives. Front Oncol 2020;10:604051. [PMID: 33634025 DOI: 10.3389/fonc.2020.604051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|